ES2095258T3 - Nuevo virus de la enfermedad de la bolsa infecciosa. - Google Patents

Nuevo virus de la enfermedad de la bolsa infecciosa.

Info

Publication number
ES2095258T3
ES2095258T3 ES90915645T ES90915645T ES2095258T3 ES 2095258 T3 ES2095258 T3 ES 2095258T3 ES 90915645 T ES90915645 T ES 90915645T ES 90915645 T ES90915645 T ES 90915645T ES 2095258 T3 ES2095258 T3 ES 2095258T3
Authority
ES
Spain
Prior art keywords
infectious
virus
new viruses
disease
bag disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90915645T
Other languages
English (en)
Inventor
David Snyder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Maryland at Baltimore
University of Maryland at College Park
Original Assignee
University of Maryland at Baltimore
University of Maryland at College Park
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Maryland at Baltimore, University of Maryland at College Park filed Critical University of Maryland at Baltimore
Application granted granted Critical
Publication of ES2095258T3 publication Critical patent/ES2095258T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
    • A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
    • A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
    • A21D2/36—Vegetable material
    • A21D2/364—Nuts, e.g. cocoa
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE IDENTIFICA EN FORMA ESENCIALMENTE PURA, UN NUEVO VIRUS NO NEUTRALIZADO O ENLAZADO MEDIANTE ANTICUERPOS MONOCLONALES QUE NEUTRALIZAN EN GRUPO TODAS LAS VACUNAS IBDV ACTUALES, Y CAPAZ DE INDUCIR LA ENFERMEDAD BURSAL INFECCIOSA EN LAS AVES. SE DESCRIBE, UN EQUIPO DE EXAMEN, Y UN ENSAYO PARA DETECTAR EL VIRUS, JUNTO CON LA VACUNA QUE INCORPORA EL VIRUS.
ES90915645T 1989-10-18 1990-09-27 Nuevo virus de la enfermedad de la bolsa infecciosa. Expired - Lifetime ES2095258T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42375789A 1989-10-18 1989-10-18

Publications (1)

Publication Number Publication Date
ES2095258T3 true ES2095258T3 (es) 1997-02-16

Family

ID=23680061

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90915645T Expired - Lifetime ES2095258T3 (es) 1989-10-18 1990-09-27 Nuevo virus de la enfermedad de la bolsa infecciosa.

Country Status (10)

Country Link
EP (1) EP0496787B1 (es)
JP (1) JPH05504049A (es)
AT (1) ATE145236T1 (es)
AU (1) AU6605190A (es)
CA (1) CA2067397A1 (es)
DE (1) DE69029145T2 (es)
ES (1) ES2095258T3 (es)
NZ (1) NZ235474A (es)
WO (1) WO1991005569A1 (es)
ZA (1) ZA908260B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL103939A (en) * 1992-12-01 1996-09-12 Abic Ltd An anti-DBI vaccine in birds containing attenuated live DBI virus
US5871744A (en) * 1996-09-05 1999-02-16 University Of Maryland-Biotechnology Inst. Method for generating birnavirus from synthetic RNA transcripts
EP0861665A1 (en) * 1997-02-03 1998-09-02 Dimminaco Ag/Sa/Ltd. Infectious bursitis vaccine
US6231868B1 (en) 1997-09-30 2001-05-15 University Of Maryland-Biotechnology Institute Method for generating nonpathogenic infections birnavirus from synthetic RNA transcripts
US7338661B2 (en) 2004-03-12 2008-03-04 Wyeth Infectious bursal disease virus antigenic isolates and vaccines

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4530831A (en) * 1982-11-02 1985-07-23 Akzo N.V. Infectious Bursal Disease vaccine
US4824668A (en) * 1987-03-09 1989-04-25 Sterwin Laboratories Inc. Attenuated infectious bursal disease virus strain and vaccine therefrom
US5064646A (en) * 1988-08-02 1991-11-12 The University Of Maryland Novel infectious bursal disease virus
US4956452A (en) * 1987-06-14 1990-09-11 The University Of Maryland Monoclonal antibody which neutralizes multiple strains of infectious bursal disease virus

Also Published As

Publication number Publication date
NZ235474A (en) 1992-12-23
DE69029145T2 (de) 1997-05-07
WO1991005569A1 (en) 1991-05-02
AU6605190A (en) 1991-05-16
EP0496787A4 (en) 1993-04-28
EP0496787B1 (en) 1996-11-13
ATE145236T1 (de) 1996-11-15
DE69029145D1 (de) 1996-12-19
JPH05504049A (ja) 1993-07-01
EP0496787A1 (en) 1992-08-05
CA2067397A1 (en) 1991-04-19
ZA908260B (en) 1991-08-28

Similar Documents

Publication Publication Date Title
FI910497A0 (fi) Nytt virus vid infektioes bursalsjukdom.
ATE131067T1 (de) Impfstoff gegen das fortpflanzungs- und atmungssyndrom bei schweinen (prrs) und diagnose.
DE3677494D1 (de) Virus-impfstoff.
BR9306984A (pt) Análogo de antígeno de peptídeo de um antígeno de peptídeo nativo vacina anticorpo processo para vacinar um hospedeiro necessitando deste tratamento estojo diagnóstico processos para preparar um análogo de um antiígeno de um antígeno de peptídeo nativo para preparar uma vacina para analisar uma amostra para um antígeno de peptídeo nativo e para analisar uma amostra para um anticorpo
NO870412L (no) Peptider.
ZA872166B (en) Synthetic htlv-iii peptides,compositions and uses thereof
DK0755684T3 (da) Vaccinekonjugat
ES2095258T3 (es) Nuevo virus de la enfermedad de la bolsa infecciosa.
ES2056075T3 (es) Anticuerpos monoclonales para regiones especificas antigenicas del virus de inmunodeficiencia humana y procedimientos para su uso.
DE69333730D1 (de) Impfstoff, der acemannan als adjuvans enthält
KR920007636A (ko) 신규의 백신체
Bouges-Bocquet et al. In vitro genetic constructions devised to express given antigenic determinants at the surface of gram-negative bacteria.
FI972658A (fi) Menetelmä rokotteen valmistamiseksi siipikarjan tarttuvaa bursaalitautia vastaan
Erdei et al. Use of the ELISA-test for the serological screening for Aujeszky's virus infection in large-scale swine stocks.
Egorenkova et al. Use of enzyme-immunoassay with Staphylococcus protein A/peroxidase conjugate in serodiagnosis of influenza.
Njayou et al. Preparation and evaluation of an IgG-Lucifer Yellow carbohydrazide conjugate for the detection of measles antigen
SE8701294L (sv) Hiv-peptid
ES2055687T3 (es) Vacuna de virus.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 496787

Country of ref document: ES